IGC Pharma, Inc.IGCEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Bradbury Strategic Investment Fund A | 18.30% | 13.8M | flat | 2024-08-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | PRINS RICHARD K | Director | Option exercise | 100.0K | $0.00 | $0 |
| 2026-04-01 | PRINS RICHARD K | Director | Option exercise | 70.0K | $0.00 | $0 |
| 2026-04-01 | Moran James P | Director | Option exercise | 80.0K | $0.00 | $0 |
| 2026-04-01 | Moran James P | Director | Option exercise | 50.0K | $0.00 | $0 |
| 2026-04-01 | Ram Mukunda | CEO | Option exercise | 333.3K | $0.00 | $0 |
| 2026-04-01 | Ram Mukunda | CEO | Option exercise | 323.1K | $0.26 | $84.0K |
| 2026-04-01 | Ram Mukunda | CEO | Option exercise | 16.7K | $0.00 | $0 |
| 2026-04-01 | Ram Mukunda | CEO | Option exercise | 33.3K | $0.00 | $0 |
| 2026-04-01 | GRIMALDI CLAUDIA | PFO | Option exercise | 100.0K | $0.00 | $0 |
| 2026-04-01 | GRIMALDI CLAUDIA | PFO | Option exercise | 138.5K | $0.26 | $36.0K |
1–10 of 11
Page 1 / 2